Donepezil, rivastigmine, galantamine and memantine for ...
Donepezil, rivastigmine, galantamine and memantine for ...
Donepezil, rivastigmine, galantamine and memantine for ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
TABLE 49 Outline detail on the modelling methods/structure used in the cost-effectiveness literature <strong>for</strong> donepezil (cont’d)<br />
Stewart et al., Jönsson et al., O’Brien et al., Neumann et al., Ikeda et al., Fagnani et al., Industry submission<br />
199882 199984a 199985 199986 200287 200389 Total annual costs<br />
(UK£) by severity<br />
group (excluding drug<br />
cost)<br />
Severe £25,488<br />
Moderate £17,950<br />
Mild £13,327<br />
Minimal £9,515<br />
Monthly costs (Euro)<br />
by MMSE score:<br />
Home care<br />
>20 192<br />
16–20 659<br />
11–15 1319<br />
≤ 10 4105<br />
Non-medical/medical<br />
institution<br />
>20 682/891<br />
16–20 923/1131<br />
11–15 1083/1292<br />
≤ 10 1340/1548<br />
Values <strong>for</strong> cost inputs<br />
are not given<br />
although the values<br />
from which cost<br />
inputs were<br />
calculated are<br />
provided<br />
Costs (US$) by stage<br />
<strong>and</strong> setting<br />
Mi/C 46,277<br />
Mi/N 46,776<br />
Mo/C 56,559<br />
Mo/N 57,170<br />
S/C 65,695<br />
S/N 66,404<br />
Expected costs<br />
(Can$) per 6-month<br />
cycle by MMSE score<br />
21–26 3,719<br />
15–20 6,754<br />
10–14 10,765<br />
Change language